quick overview

product name liraglutide;
cas no. 204656-20-2;
sequence h-his-ala-glu-gly-thr-phe-thr-ser-asp-val-ser-ser-tyr-leu-glu-gly-gln-ala-ala-lys(n-ε-(nα-palmitoyl-l-γ-glutamyl))-glu-phe-ile-ala-trp-leu-val-arg-gly-arg-gly-oh;
molecular formula c172h265n43o51;
molar mass 3751.202 g/mol;
purity ≥98%;
impurity ≤0.5% ;
storage temperature 2-8℃;
packing size 1g/bottle, 10g/bottle,50g/bottle or at customers reqirement.

function: liraglutide is for the treatment of diabetes type 2.

mechanism of actions: liraglutide is a glucagon-like peptide-1 (glp-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cv death in adults with type 2 diabetes and established cv disease.
it was approved by the fda on december 23, 2014 and by the european medicines agency on january 23, 2015, for adults with a body mass index (bmi) of 30 or greater (obesity) or a bmi of 27 or greater (overweight) who have at least one weight-related condition.

originator company: novo nordisk

dosage for finished formulation: 18 mg/3ml

similar effect peptides: exenatide, semaglutide

generic api process in our company: liraglutide is one of our main peptide projects, related documents will be submitted to the international fda.